Calidi to Effect Reverse Stock Split [Yahoo! Finance]
Calidi Biotherapeutics, Inc. (CLDI)
Company Research
Source: Yahoo! Finance
SAN DIEGO, July 05, 2024 BUSINESS WIRE )--Calidi Biotherapeutics Inc. (NYSE American: CLDI) ("Calidi" or "Company"), a clinical-stage biotechnology company developing a new generation of targeted virotherapies, today announced that its Board of Directors has approved the reverse stock split of its outstanding shares of common stock at a ratio of 1-for-10 (the "Reverse Stock Split"). The Reverse Stock Split is expected to become effective at 12:01 a.m. Eastern Time on July 15, 2024. The Company's common stock is expected to commence trading on a split-adjusted basis when the NYSE American market opens on July 15, 2024 under the existing symbol of "CLDI." The new CUSIP number for the Company's common stock following the Reverse Stock Split will be 320703 309. Calidi's publicly-traded warrants will continue to be traded on the NYSE American under the symbol "CLDI WS" and the CUSIP for the publicly-traded warrants will not change. At the Special Meeting of Stockholders held on June 6,
Show less
Read more
Impact Snapshot
Event Time:
CLDI
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CLDI alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CLDI alerts
High impacting Calidi Biotherapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
CLDI
News
- Calidi Biotherapeutics Announces FDA Clearance of the Northwestern University IND Application for CLD-101 Clinical Trial in High-Grade GliomaGlobeNewswire
- Calidi Biotherapeutics Reports Second Quarter 2024 Operating and Financial Results [Yahoo! Finance]Yahoo! Finance
- Calidi Biotherapeutics Reports Second Quarter 2024 Operating and Financial ResultsGlobeNewswire
- Calidi Biotherapeutics Announces Launch of Nova Cell Subsidiary and $3 Million Aggregate Investment from Dr. Ronald RigorGlobeNewswire
- Calidi Biotherapeutics Announces Issuance of New U.S. Patent Covering Novel SuperNova Technology PlatformGlobeNewswire
CLDI
Sec Filings
- 10/1/24 - Form S-3
- 10/1/24 - Form S-8
- 9/30/24 - Form 4
- CLDI's page on the SEC website